JAK2 mutational status and the contribution of TERT and JAK2 polymorphisms to the occurrence of myeloproliferative neoplasms in Eastern Morocco
African Health Sciences · 2024
DOI: 10.4314/ahs.v24i3.18 ↗Kurz gefasst
Fachartikel in der Zeitschrift African Health Sciences, 2024. Verfasst von Karam Yahya Belmokhtar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Genetics Unit, Medical Sciences Research Laboratory, Faculty of Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco. Hauptthemen laut MEDLINE: Janus Kinase 2, Myeloproliferative Disorders, Telomerase. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The JAK2 V617F somatic mutation is a hallmark of myeloproliferative neoplasms (MPN) and is present in some patients with splanchnic venous thrombosis (SVT).
Objectives
We investigated for the first time in Eastern Morocco the JAK2 mutational status and germline risk factors, such as the TERT and JAK2 polymorphisms, in MPN and SVT patients.
Methods
This study included 38 patients with MPN, 24 patients presenting with SVT and 60 healthy donors from the BRO Biobank. JAK2 mutations were analyzed using qPCR and Sanger sequencing. Predisposing polymorphisms to MPN were evaluated using Sanger sequencing.
Results
JAK2 V617F mutation was positive in 64.5% of patients with MPN and 20.8% of patients with SVT. The JAK2 V617F allelic burden ranged from 2% to 97.53%. We found a strong association between the JAK2 rs56241661 polymorphism of the JAK2 46/1 haplotype and the development of MPN. However, no association was detected between the TERT rs2736100 polymorpism and MPN.
Conclusion
The JAK2 mutational status and its allelic burden in Eastern Morocco are consistent with previous studies. The JAK2 46/1 haplotype was strongly associated with MPN. However, unlike other previously studied populations, the TERT polymorphism rs2736100 has no effect on the occurrence of MPN in our population. Keywords: Myeloproliferative neoplasms; JAK2 V617F; TERT and JAK2 polymorphisms; genetic predisposition; Morocco.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genetics Unit, Medical Sciences Research Laboratory, Faculty of Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
- Department of Internal Medicine, Mohammed VI University Hospital, Laboratory of Immunohematology and Cellular Therapy, Faculty of Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
- El Farabi Regional Hospital, Oujda, Morocco.
- Transfusion Regional Centre, Oujda, Morocco.
Zitieren
APA
Belmokhtar, K. Y., Errahhali, M. E., Lhousni, S., Errahhali, M. E., Bouagaga, R., Ouarzane, M., Charif, M., Attar, N. A., Sidqi, Z., Hamaz, S., Bachir, H., Serraj, K. A., Boulouiz, R., Alaoui, H., & Bellaoui, M. (2024). JAK2 mutational status and the contribution of TERT and JAK2 polymorphisms to the occurrence of myeloproliferative neoplasms in Eastern Morocco. African Health Sciences. https://doi.org/10.4314/ahs.v24i3.18
Vancouver
Belmokhtar KY, Errahhali ME, Lhousni S, Errahhali ME, Bouagaga R, Ouarzane M, et al. JAK2 mutational status and the contribution of TERT and JAK2 polymorphisms to the occurrence of myeloproliferative neoplasms in Eastern Morocco. African Health Sciences. 2024. doi:10.4314/ahs.v24i3.18
BibTeX
@article{Belmokhtar2024,
author = {Belmokhtar, Karam Yahya and Errahhali, Mounia Elidrissi and Lhousni, Saida and Errahhali, Manal Elidrissi and Bouagaga, Rachida and Ouarzane, Meryem and Charif, Majida and Attar, Nadia Al and Sidqi, Zaina and Hamaz, Siham and Bachir, Houda and Serraj, Khalid Andaloussi and Boulouiz, Redouane and Alaoui, Habiba and Bellaoui, Mohammed},
title = {JAK2 mutational status and the contribution of TERT and JAK2 polymorphisms to the occurrence of myeloproliferative neoplasms in Eastern Morocco},
journal = {African Health Sciences},
year = {2024},
doi = {10.4314/ahs.v24i3.18}
}
EUVIMED